Skip to main content
. Author manuscript; available in PMC: 2014 Feb 11.
Published in final edited form as: Breast Cancer Res Treat. 2013 May 17;139(2):607–616. doi: 10.1007/s10549-013-2562-6

Fig. 2.

Fig. 2

Mean cognitive function score (CFS) by treatment arm over time. Mid-treatment, doxorubicin–cyclophosphamide (AC): day 29; end of treatment, AC: 4–5 months. Mid-treatment, cyclophosphamide–methotrexate–5-fluorouracil (CMF): day 77; end of treatment, CMF: 6–7 months. Mid-treatment, capecitabine: day 63; end of treatment, capecitabine: 4–5 months. Error bars represent 95 % CI for the adjusted average cognitive function score (CFS)

HHS Vulnerability Disclosure